详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The development of cancers research based on mitochondrial heat shock protein 90

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]West China Hospital of Sichuan University, Sichuan University, Chengdu, China. [2]Institute of Medical Microbiology and Hygiene, Faculty of Medicine, University of Freiburg, Freiburg, Germany. [3]Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, Centre for Safe Medication Practice and Research, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China. [4]School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China. [5]Multiscale Research Institute of Complex Systems, Fudan University, Shanghai, China. [6]Shanghai Jiao Tong University School of Medicine, Shanghai, China. [7]School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. [8]Department of Organ Transplantation, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China. [9]Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.

出处：

DOI：

ISSN：

关键词： mtHsp90 TRAP1 molecular chaperone mitochondria gamitrinib

摘要：

Mitochondrial heat shock protein 90 (mtHsp90), including Tumor necrosis factor receptor-associated protein 1 (TRAP1) and Hsp90 translocated from cytoplasm, modulating cellular metabolism and signaling pathways by altering the conformation, activity, and stability of numerous client proteins, and is highly expressed in tumors. mtHsp90 inhibition results in the destabilization and eventual degradation of its client proteins, leading to interference with various tumor-related pathways and efficient control of cancer cell development. Among these compounds, gamitrinib, a specific mtHsp90 inhibitor, has demonstrated its safety and efficacy in several preclinical investigations and is currently undergoing evaluation in clinical trials. This review aims to provide a comprehensive overview of the present knowledge pertaining to mtHsp90, encompassing its structure and function. Moreover, our main emphasis is on the development of mtHsp90 inhibitors for various cancer therapies, to present a thorough overview of the recent pre-clinical and clinical advancements in this field.Copyright © 2023 Xiang, Liu, Sun, Liao, Liu, Zhao, Feng, Liu and Wang.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]West China Hospital of Sichuan University, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [2]Institute of Medical Microbiology and Hygiene, Faculty of Medicine, University of Freiburg, Freiburg, Germany. [9]Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Molecular basis of binding between the global post-transcriptional regulator CsrA and the T3SS chaperone CesT. [2]Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma [3]Targeting cancer cell mitochondria as a therapeutic approach: recent updates [4]Adiponectin deficiency accelerates brain aging via mitochondria-associated neuroinflammation [5]Mitochondrial fission factor: a living way for mitochondria sensing food [6]Editorial: The diversified role of mitochondria in cancer [7]An Overview: The Diversified Role of Mitochondria in Cancer Metabolism [8]A novel mitochondria-targeting compound exerts therapeutic effects against melanoma by inducing mitochondria-mediated apoptosis and autophagy in vitro and in vivo [9]Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells. [10]NDRG2 promotes adriamycin sensitivity through a Bad/p53 complex at the mitochondria in breast cancer.